A peptide vaccine, containing human tumor-associated epithelial mucin (MUC1) conjugated with keyhole limpet hemocyanin (KLH), with potential antineoplastic activity. Vaccination with MUC1-KLH conjugate vaccine may stimulate humoral and cytotoxic T-lymphocyte (CTL) responses against tumor cells expressing the MUC1 antigen. In this vaccine, MUC1 antigen is conjugated with KLH, an immunostimulant and a hapten carrier, to enhance immune recognition. MUC1 antigen, a membrane-bound glycoprotein expressed by most glandular and ductal epithelial cells, is overexpressed in an aberrant or deglycosylated form in various cancers such as those of the breast, prostate, and ovary.
Leave a Comment